Catalog No.
FHJ28813
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Conjugation
APC
Target
Leucine-rich repeat protein induced by beta-amyloid homolog, LRRC15, Leucine-rich repeat-containing protein 15, LIB, hLib
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Accession
Q8TF66
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Stability and Storage
Store at 4°C for 12 months. Protect from light. Do not freeze.
Clone ID
SAA0773
Impact of site-specific conjugation strategies on the pharmacokinetics of antibody conjugated radiotherapeutics., PMID:39378827
Impact of site-specific conjugation strategies on the pharmacokinetics of antibody conjugated radiotherapeutics., PMID:39378827
CAFs-Associated Genes (CAFGs) in Pancreatic Ductal Adenocarcinoma (PDAC) and Novel Therapeutic Strategy., PMID:38892190
CAFs-Associated Genes (CAFGs) in Pancreatic Ductal Adenocarcinoma (PDAC) and Novel Therapeutic Strategy., PMID:38892190
Leucine-Rich Repeat Containing 15-Mediated Cell Adhesion Is Essential for Integrin Signaling in TGF-β1-Induced PDL Fibroblastic Differentiation., PMID:38051601
Leucine-Rich Repeat Containing 15-Mediated Cell Adhesion Is Essential for Integrin Signaling in TGF-β1-Induced PDL Fibroblastic Differentiation., PMID:38051601
Development of Anti-LRRC15 Small Fragments for Imaging Purposes Using a Phage-Display ScFv Approach., PMID:36293532
Exploiting LRRC15 as a Novel Therapeutic Target in Cancer., PMID:35260879
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications., PMID:34656365
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications., PMID:34656365
Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer., PMID:34654724
Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer., PMID:34654724
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors., PMID:33820780
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors., PMID:33820780
ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium., PMID:33298592
ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium., PMID:33298592
LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies., PMID:33063919
LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies., PMID:33063919
LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications., PMID:32210091
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates., PMID:29764866
Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens., PMID:24641868
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates., PMID:29764866
For research use only. Not for human or drug use.
